Dr. Kuhn hopes to expand funding for rheumatology research and enhance the ACR’s basic and clinical research pre-conference offerings during her term as chair.
Search results for: hip OA
COVID-19 Vaccines: Implications for Rheumatology Practice & Research
In late December, the ACR convened a COVID-19 Vaccine Consortium via a conference call to consider rheumatology’s place in the massive worldwide effort to develop, test, deliver and further study the vaccines promising to bring the historic pandemic under control.
Winter 2021’s Awards, Appointments & Announcements in Rheumatology
New Appointments for Carlos Lozada, MD In the midst of the coronavirus pandemic, Carlos J. Lozada, MD, FACP, FACR, professor of clinical medicine, University of Miami Miller School of Medicine, has expanded his professional and volunteer duties. In May he was appointed chief (interim) of the Division of Rheumatology at the Miller School of Medicine,…
Rheum After 5: Introducing Dr. Grayson & the Affordable Rock ‘n’ Roll Act
Peter Grayson, MD, MSc, a tenure track investigator at the National Institutes of Health (NIH) Intramural Research Program, Bethesda, Md., sometimes wonders how his life would have turned out if the band he was playing in during college had signed a recording contract with a major record label. Dr. Grayson has been playing the piano…
Case Report: Is It Reactive or IBD-Associated Arthritis?
Reactive arthritis is classically associated with an infectious etiology, such as Salmonella, Yersinia, Campylobacter, Chlamydia or gonorrhea. Clostridium difficile is a rare, and recently recognized, causative agent for this condition.1 Case Presentation The patient is a 21-year-old man with a past medical history significant for hereditary spherocytosis and Crohn’s disease, complicated by an anorectal fistula,…
The Science of Empathy in Rheumatology
Rheumatology has arguably benefited like no other field from the proliferation of an increasingly effective pipeline of therapeutics. These medications have dramatically raised the bar for clinical outcomes for our patients in a way that we could not have envisioned a short generation ago. With such therapeutic progress now reaching a widening circle of rheumatic…
The State of Clinical Research in Vasculitis: 2021
It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…
‘Communication Is More Important Than Ever’: A Q&A with Howard M. Busch, DO
As founder and president of a large rheumatology group, Howard M. Busch, DO, says the pandemic has had a limited financial effect on many of the network’s clinics. Communication and technology have been key to adapting to the needs of patients and connecting with other providers during this critical time.
Advancing the ACR’s Legislative Priorities in 2021
With a new Congress and many new legislators in key leadership positions, your support today will help RheumPAC start the year off strong.
ACR Advocacy: 2020 Year in Review
As a new year begins, Government Affairs Committee Chair Blair Solow, MD, takes stock of ACR advocacy wins in 2020 and issues to watch in 2021, including workforce issues, continued telemedicine access, prior authorization relief, Medicare reimbursement and drug pricing.
- « Previous Page
- 1
- …
- 102
- 103
- 104
- 105
- 106
- …
- 323
- Next Page »